| Oct 29 |
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
|
| Oct 18 |
Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
|
| Oct 16 |
Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024
|
| Oct 11 |
Sagimet gains on peer-reviewed data for lead asset in MASH
|
| Oct 11 |
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
|
| Oct 1 |
Sagimet soars on FDA breakthrough therapy designation for its liver disease treatment
|
| Oct 1 |
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
|
| Oct 1 |
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Sep 12 |
Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit
|
| Sep 4 |
Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
|
